Cheapest GLP-1 Options Without Insurance [2026]

Last updated: August 2026

Quick Answer:

Lilly Direct self-pay vials now list Zepbound (tirzepatide) at $299/month for the 2.5 mg starter dose, $399/month for 5 mg, and $449/month for 7.5 mg–15 mg — provided you refill within 45 days of your last delivery. Miss that window and the higher doses jump to $599–$1,049.
Compounded semaglutide from telehealth platforms still runs roughly $169–$299/month, but the legal lane narrowed sharply in 2026: the FDA has proposed permanently banning bulk compounding of semaglutide and tirzepatide, and dozens of telehealth firms have received warning letters.
The TrumpRx portal (launched February 5, 2026) lists Ozempic and the Wegovy injection pen at $199/month, the Wegovy pill at $149/month, and Zepbound at $299/month, under the November 6, 2025 pricing agreements with Novo Nordisk and Eli Lilly.
GoodRx's introductory pricing brings Ozempic or Wegovy injections to $199/month for the first two fills, and a GoodRx coupon can bring Zepbound as low as $299/month — a sharp drop from the ~$995–$1,090 street prices seen in past years (GoodRx — Zepbound).
Brand-name retail without any discount is still expensive — roughly Ozempic $968–$1,028, Wegovy $1,349–$1,637, Mounjaro ~$1,069, Zepbound pen $1,059–$1,087 — but in 2026 almost nobody who knows the current programs needs to pay those list prices.
This page is informational only. Pricing and program rules change monthly, and any prescription decision should run through a licensed clinician — not a Google search.

What cash-pay patients were reporting in 2025 — and what's changed since

Cash-pay patients on forums like r/Zepbound, r/Mounjaro, and r/Ozempic spent 2025 comparing notes on which self-pay channel was cheapest. The consistent pattern reported at the time: LillyDirect's self-pay vials for Zepbound were priced at $349/month for the 2.5 mg starter dose and $499/month for 5–10 mg, while NovoCare's Wegovy self-pay price sat around $499/month, with SingleCare Ozempic coupons landing closer to $800–$900/month at retail pharmacies. That matches Eli Lilly's and Novo Nordisk's own pricing announcements from that period.

Those numbers are now out of date. Lilly cut LillyDirect Zepbound pricing again in 2026 (to the $299/$399/$449 tiers above), and the TrumpRx portal and expanded NovoCare/GoodRx introductory offers pushed brand-name injectable prices for new patients down to $149–$299/month for a starting dose. If you're comparing quotes against something you read on Reddit from 2025, assume the price has moved — check the manufacturer's own pricing page before paying.

Affiliate disclosure: This article contains affiliate links. We may earn a commission if you make a purchase through our links, at no extra cost to you.

GLP-1 medications transformed weight loss and Type 2 diabetes management between 2023 and 2025. The sticker shock kept millions of Americans from accessing them, and full retail pricing is still steep in 2026: Ozempic runs roughly $968–$1,028, Wegovy $1,349–$1,637, Mounjaro ~$1,069, and the Zepbound auto-injector pen $1,059–$1,087, before any discount (GoodRx GLP-1 pricing index; TrumpRx.gov).

2026 brought real price relief on several fronts. Eli Lilly's direct self-pay vial program for Zepbound now lists $299 for the 2.5 mg starter dose, $399 for 5 mg, and $449 for 7.5 mg–15 mg (within a 45-day refill window) through LillyDirect.com. The TrumpRx federal portal opened February 5, 2026, listing Ozempic and Wegovy pen at $199/month, the Wegovy pill at $149/month, and Zepbound at $299/month. Novo Nordisk's NovoCare self-pay program offers new patients Wegovy at $199/month for the first two fills, stepping up to $349–$399/month afterward.

At the same time, the compounded-semaglutide market that many budget-conscious patients relied on in 2023–2025 has narrowed considerably. The FDA declared the semaglutide shortage resolved in February 2025 and has since moved toward eliminating bulk compounding entirely — proposing in spring 2026 to permanently exclude semaglutide, tirzepatide, and liraglutide from the list of substances 503B outsourcing facilities may compound. Several major telehealth brands have exited or scaled back compounded GLP-1 marketing as a result.

This guide walks through every legitimate option, the real out-of-pocket cost, and the eligibility rules. Pricing is current as of August 2026 and is subject to change — verify directly with the manufacturer or pharmacy before paying. Talk to a licensed clinician before starting, switching, or stopping any GLP-1.

The GLP-1 Price Landscape in 2026: What Everything Actually Costs

Before any savings strategy, here is the baseline. These are approximate full-retail, no-coupon, no-insurance prices at major US retail pharmacies as of mid-2026 — actual price at the counter varies by pharmacy and region:

Medication	Manufacturer	Type	Approx. Monthly Retail Price	FDA Approved For
Ozempic (semaglutide)	Novo Nordisk	Injection	$968–$1,028	Type 2 diabetes
Wegovy (semaglutide)	Novo Nordisk	Injection	$1,349–$1,637	Weight loss
Wegovy Pill	Novo Nordisk	Oral	~$1,200	Weight loss
Mounjaro (tirzepatide)	Eli Lilly	Injection	~$1,069	Type 2 diabetes
Zepbound (tirzepatide) pen	Eli Lilly	Injection	$1,059–$1,087	Weight loss
Foundayo (orforglipron)	Eli Lilly	Oral	~$349 list; $149 via TrumpRx/LillyDirect intro pricing	Weight loss (approved April 2026)
Rybelsus (semaglutide)	Novo Nordisk	Oral	~$900–$935	Type 2 diabetes
Saxenda (liraglutide)	Novo Nordisk	Injection	~$1,300–$1,430	Weight loss

Those retail numbers are almost never what a well-informed cash-pay patient actually pays in 2026. The rest of this guide walks through every option, ranked roughly cheapest to most expensive — with the actual eligibility rules and what to verify before signing up.

Option 1: Lilly Direct Self-Pay Vials — $299–$449/Month for Brand-Name Zepbound

The single highest-leverage cash-pay option in 2026 is Eli Lilly's direct-to-consumer Zepbound vial program. Lilly's own Self Pay Journey Program pricing lists the 2.5 mg starter vial at $299/month, the 5 mg vial at $399/month, and the 7.5 mg, 10 mg, 12.5 mg, and 15 mg vials at $449/month — provided the refill is placed within 45 days of the previous delivery (LillyDirect Zepbound self-pay terms).

Two things make this program meaningfully different from a coupon:

It is brand-name tirzepatide direct from the manufacturer. Same molecule, same potency, same FDA approval as the auto-injector pen — just delivered in a single-dose vial that the patient draws with a syringe.
The price is fixed and published, not negotiated coupon-by-coupon at the pharmacy counter.

Miss the 45-day refill window and the higher-dose vials revert to standard self-pay pricing: 7.5 mg $599, 10 mg $699, 12.5 mg $849, 15 mg $1,049. Set a refill reminder — the discount lapses automatically, not as a penalty but simply because you fall out of the program's cadence rules.

A practical caveat reported by long-time Zepbound patients: vials require manual draw with a syringe rather than the auto-injector pen, which is a meaningful workflow shift for anyone who started on the pens. The cost savings are large enough that most cash-pay patients accept the trade — but it is worth knowing before signing up.

For a side-by-side of brand-name versus compounded tirzepatide, see Option 1B below.

Option 1A: Compounded Semaglutide — Still Available, But the Legal Lane Has Narrowed Sharply

Compounded semaglutide was the cheapest GLP-1 path during the 2023–2024 Ozempic/Wegovy shortage. In 2026, it still exists, but the regulatory ground has shifted significantly — and patients should weigh that before choosing this route.

How the 2026 FDA Crackdown Changed Things

The FDA officially declared the semaglutide shortage resolved on February 21, 2025, which removed the shortage-based legal exception that let compounders mass-produce copies of a commercially available drug. Since then, enforcement has escalated fast:

In spring 2026 (proposal published in the Federal Register around April 30–May 2026), the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the list of substances 503B outsourcing facilities are allowed to compound in bulk. The public comment period runs through June 29, 2026 — this is a proposed rule, not yet final, but it signals where the agency is heading.
The FDA has issued 50+ warning letters to compounding pharmacies and telehealth companies in 2026 alone, including roughly 30 sent to telehealth firms in February 2026 and additional rounds through the summer — the largest wave of GLP-1 compounding enforcement to date.
Novo Nordisk sued Hims & Hers in February 2026 over its marketing of compounded semaglutide; the companies resolved the case in March 2026 with Hims & Hers agreeing to stop promoting compounded GLP-1 products and instead sell Novo Nordisk's FDA-approved Ozempic and Wegovy at self-pay prices. Hims is no longer a compounded-semaglutide option as of that agreement.
503A pharmacies can still legally compound semaglutide for individual patients under patient-specific prescriptions when a documented medical need exists (e.g., an allergy to an inactive ingredient, or a dose not commercially available). Several platforms continue to operate in this narrower lane; others have kept offering compounded product despite manufacturer partnership terms that were supposed to end it, which independent reporting has flagged as a gray-area compliance issue worth watching.

Always verify a pharmacy's accreditation status, 503A vs. 503B designation, and specific medical-need documentation before paying — and check the provider's own site for current terms, since this market is moving fast.

Compounded Pricing Reported by Providers (mid-2026)

These are prices providers publish on their own sites as of mid-2026. They change frequently and should be verified directly before signing up — treat this table as a starting point, not a guarantee:

Provider	Monthly Cost	Pharmacy Type
Peak Wellness	$149–$249/month (promotional first month lower)	503A
GobyMeds	$169–$299/month	telehealth-network
MEDVi	$179–$299/month injectable; $249–$369/month oral	503A
SynergyRx	~$200–$347/month	telehealth-network
Henry Meds	$249–$397/month	503A

Note: MEDVi received an FDA warning letter in February 2026 for labeling that implied it was itself the compounding pharmacy rather than a telehealth intermediary — a reminder to check who is actually compounding the medication, not just who is marketing it. Hims & Hers is excluded from this list — it exited the compounded-semaglutide market in its March 2026 settlement with Novo Nordisk and now sells FDA-approved Ozempic/Wegovy at self-pay prices instead.

Prices are listed for context only and are not a recommendation to compound. Patients should weigh compounded semaglutide against brand-name options like Lilly Direct or NovoCare self-pay (different regulatory status, same active ingredient in the case of semaglutide) with a licensed clinician who can review their specific medical history.

What to Watch Out For

Look for these before paying any compounding pharmacy:

PCAB accreditation (Pharmacy Compounding Accreditation Board) — the established quality standard
503A versus 503B designation clearly disclosed
Certificate of Analysis for each batch showing potency and sterility testing
USP 797/795 compliance for sterile compounding standards
Whether the company is actually the compounding pharmacy, or just a telehealth front end routing prescriptions to a separate pharmacy — ask directly

The FDA has received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide as of its most recent public accounting, with many tied to dosing errors from patients drawing their own doses out of multidose vials without proper instruction. Separately, FDA warning letters have documented specific cases of quality failures — one 2025 warning letter cited a compounding pharmacy whose semaglutide injection tested at only 79.9% of labeled potency, alongside multiple lots that failed sterility testing between July 2024 and May 2025 (FDA — concerns with unapproved GLP-1 drugs).

For a deeper dive into safety considerations, see our compounded semaglutide safety guide.

Option 1B: Compounded Tirzepatide (~$200–$400/Month)

A significant development in the compounded market is the growing availability of compounded tirzepatide, giving patients who want the dual GIP/GLP-1 mechanism a more affordable path than brand-name Mounjaro or Zepbound — though it sits under the same 2026 regulatory pressure described above.

Why This Matters

Tirzepatide has shown stronger average weight loss than semaglutide in head-to-head clinical trials, but historically the only widely available compounded option was semaglutide. That gap closed somewhat in 2025–2026. Several telehealth platforms now offer compounded tirzepatide at prices below the $1,059–$1,069+ retail cost of brand-name versions — though, as with compounded semaglutide, the FDA's proposed 503B bulk-compounding ban (comment period through June 29, 2026) would eliminate large-scale compounding of tirzepatide too if finalized.

Compounded Tirzepatide Pricing Reported by Providers (mid-2026)

Provider	Monthly Cost	Notes
GobyMeds	~$169–$299/month	12-week starter bundle discounts available
SynergyRx	~$299–$347/month	Medication + consultation
Peak Wellness	~$249–$347/month	Medication + provider visits
Henry Meds	~$397/month	Medication + monthly check-ins

These figures are self-reported by each provider and change often — confirm current pricing directly on the provider's site before enrolling.

Key Considerations

Compounded tirzepatide carries the same quality concerns as compounded semaglutide — verify the pharmacy's 503A/503B registration and PCAB accreditation before ordering. The market for compounded tirzepatide is less mature than semaglutide, so fewer providers offer it. Even so, paying roughly $200–$400/month versus $1,059+/month for brand-name tirzepatide is a large discount for patients who specifically want tirzepatide and are comfortable with the current regulatory uncertainty.

Option 2: TrumpRx Portal + Manufacturer Deals ($149–$299/Month)

The TrumpRx program, launched February 5, 2026, represents the biggest federal intervention in GLP-1 pricing to date.

What TrumpRx Actually Does

TrumpRx (trumprx.gov) is not a pharmacy. It is a government portal, built on the November 6, 2025 Most-Favored-Nation pricing agreements the Trump administration reached with Novo Nordisk and Eli Lilly, that routes patients to the manufacturers' own direct-pay channels (NovoCare and LillyDirect) at negotiated prices.

Current TrumpRx Pricing for GLP-1s

As listed on trumprx.gov:

Medication	TrumpRx Price	Reduced From (List Price)
Wegovy pill	$149/month	~$1,349
Wegovy pen (injectable)	$199/month	~$1,349
Ozempic (injectable)	$199/month	~$1,028
Zepbound (injectable)	$299/month	~$1,087

The Backstory

On November 6, 2025, the Trump administration reached agreements with both Novo Nordisk and Eli Lilly to substantially reduce GLP-1 prices, in exchange for the manufacturers avoiding potential tariffs and committing billions of dollars to expand US manufacturing (Novo Nordisk $10 billion, Eli Lilly $27 billion). These deals cover Wegovy, Ozempic, Zepbound, and Lilly's newly approved oral GLP-1 Foundayo (orforglipron) for uninsured patients and certain Medicare recipients.

Separately, the Medicare GLP-1 Bridge program launched July 1, 2026, giving eligible Medicare Part D members access to Wegovy, Zepbound, and Foundayo for a $50 copay per 30-day supply (not counted toward the Part D deductible or out-of-pocket max) through December 31, 2027. This program covers the weight-loss-indicated drugs specifically — Ozempic and Mounjaro, which are approved for diabetes rather than weight loss, are handled through standard Part D diabetes-drug coverage, not the Bridge program.

How to Use TrumpRx

Visit trumprx.gov
Enter your medication name
The portal shows available manufacturer pricing and routes you to NovoCare or LillyDirect
You complete enrollment through the manufacturer's own self-pay portal
No income verification required

TrumpRx Limitations to Know

TrumpRx pricing is not always the cheapest option available. For semaglutide specifically, compounded versions from telehealth platforms can still beat TrumpRx's $199/month price by $50–$100/month, though that gap has narrowed as brand-name self-pay prices have fallen. For tirzepatide (Zepbound), TrumpRx's $299/month is competitive with — and sometimes cheaper than — compounded alternatives, and it comes with FDA approval.

Also worth noting: patients with government-funded insurance, including Medicare and Medicaid, are generally directed to the separate Medicare GLP-1 Bridge program rather than the TrumpRx self-pay pricing, which is designed for the uninsured and commercially insured whose plans don't cover GLP-1s.

Option 3: GoodRx Coupons and Manufacturer Intro Offers ($149–$399/Month)

GoodRx remains one of the most accessible savings tools for brand-name GLP-1 medications, and both GoodRx and the manufacturers themselves have active introductory pricing for GLP-1s in 2026.

Brand-Name GLP-1 Introductory Pricing (mid-2026)

Medication	Introductory Price	Offer Details	Ongoing Price
Ozempic / Wegovy injection	$199/month (first 2 fills)	Novo Nordisk self-pay offer	$349/month (0.25–2.4mg), $399 for Wegovy HD
Wegovy pill (1.5mg, 4mg)	$149/month	4mg offer valid through Aug 31, 2026	$199/month for 4mg after Aug 31, 2026
Zepbound (vial, self-pay)	$299/month (2.5mg)	LillyDirect Self Pay Journey Program	$399–$449/month by dose (within 45-day refill window)

GoodRx coupons can also bring Zepbound as low as roughly $299/month at participating pharmacies — down substantially from the ~$995–$1,090 street prices seen with older coupons, largely because Lilly's own self-pay price cuts have pulled the whole market lower. GoodRx also offers a low-cost telemedicine subscription for weight-loss consultations, which covers the prescription visit but not the medication itself.

The GoodRx Strategy

The manufacturer introductory pricing (via GoodRx or direct from NovoCare/LillyDirect) makes the first two months very cheap for brand-name drugs. The jump to $349–$399/month for ongoing Wegovy fills makes it less competitive long-term compared to LillyDirect's Zepbound vial pricing or the TrumpRx portal. Our recommended approach: use introductory pricing while you evaluate longer-term options, then switch to whichever program delivers the best ongoing value for your specific medication and dose.

For a complete breakdown of costs across all GLP-1 medications, check our GLP-1 medication cost guide and our how much does GLP-1 medications cost in 2026 complete pricing guide.

Option 4: Manufacturer Savings Programs ($0–$500/Month)

Both Novo Nordisk and Eli Lilly operate patient assistance programs that can dramatically reduce or even eliminate costs for qualifying patients. For a side-by-side ranking of every active savings card and discount in 2026, see our GLP-1 savings programs and discounts ranked guide.

Novo Nordisk Programs

Ozempic Savings Card: Commercially insured patients may pay as little as $25 for a 1-month or 3-month supply. Does NOT apply to uninsured patients.

NovoCare Patient Assistance Program (PAP): For uninsured patients earning under 400% of the Federal Poverty Level ($63,840 for a single person in 2026, per the January 2026 HHS poverty guidelines), Novo Nordisk provides its medications at no or reduced cost for qualifying patients. Apply directly at NovoCare.com — the income threshold is higher than most people expect.

NovoCare Pharmacy: Novo Nordisk's own direct-to-patient delivery service ships self-pay medication directly to your door, removing the friction of a participating retail pharmacy rejecting a discount code at the counter.

Eli Lilly Programs

Zepbound Savings Card: Eligible commercially insured patients whose plans don't cover Zepbound can pay as low as $25/month with the card.

Zepbound Self-Pay (LillyDirect vials): See Option 1 above for current dose-by-dose pricing ($299–$449/month within the refill window).

Lilly Cares Foundation: Provides free or reduced-cost medications for patients who are uninsured, underinsured, or cannot afford their medications, based on income eligibility. Applications can be submitted online or by phone.

Who Actually Qualifies

The income thresholds for manufacturer PAPs are higher than most people realize. If you are uninsured and earn under roughly $63,840/year as a single filer (400% of the 2026 FPL), it's worth applying to NovoCare's or Lilly Cares' assistance program before paying for any other option. For a two-person household, the comparable 400%-FPL threshold is roughly $86,000/year. Applications typically require proof of income (tax return or pay stubs) and a prescription from your provider — check each program's site for current, exact thresholds since FPL figures update annually every January.

Walgreens Weight Management Program

Walgreens launched a virtual weight-management program in February 2026 that connects self-pay patients ages 18–64 to licensed clinicians for FDA-approved GLP-1 prescriptions, currently available in 28 states. The visit itself is a flat $49 online consultation fee with no separate monthly subscription; medication (e.g., Wegovy) is billed separately starting around $149/month, priced in line with the manufacturer self-pay programs above. Availability and exact pricing vary by state — check walgreens.com.

Option 5: International Pharmacies ($200–$400/Month)

Some Americans order GLP-1 medications from Canadian or international pharmacies, where the same brand-name drugs can cost meaningfully less than US retail.

Approximate International Pricing

Medication	US Retail	Canadian Pharmacy (approx.)
Ozempic 1mg	~$1,000/month	$300–$400/month
Wegovy	~$1,350–$1,637/month	$350–$450/month
Rybelsus 14mg	~$900–$935/month	$200–$300/month

Legal Considerations

The FDA technically prohibits importing prescription medications for personal use, but enforcement has historically been limited for small quantities (roughly a 90-day supply or less) ordered by individuals for personal use, without commercial distribution involved. This is enforcement discretion, not a legal guarantee.

Risks include: receiving counterfeit products, inconsistent quality control, and potential legal exposure. If you choose this route, verify the pharmacy through the Canadian International Pharmacy Association (CIPA) or PharmacyChecker.

Important Context for 2026

International pharmacy pricing has become somewhat less attractive relative to domestic options than it was a year or two ago. With LillyDirect Zepbound vials now as low as $299/month, TrumpRx offering $199–$299/month brand-name pricing, and compounded semaglutide still available (with caveats) for under $300/month, the cost advantage of importing from Canada has narrowed. International pharmacies still make sense mainly for patients who specifically want brand-name product at a discount but don't qualify for domestic manufacturer assistance programs.

Option 6: Direct-Pay Telehealth Programs (~$150–$400/Month)

A growing category in 2026 is the direct-pay telehealth model, where platforms handle everything from the medical evaluation to medication delivery in a single relationship. These differ from pure compounding-pharmacy plays in that several now emphasize FDA-approved brand-name product alongside — or instead of — compounded options, following the 2026 enforcement wave.

How Direct-Pay Programs Work

You sign up, complete a health questionnaire, have a video or async consultation with a licensed provider, and if approved, receive your medication by mail. No insurance filing, no pharmacy visits, no surprise bills.

Notable Direct-Pay Programs (mid-2026)

Provider	Approx. Monthly Cost	What's Included	Medication Type
Hims & Hers	$199+/month (self-pay Ozempic/Wegovy)	Provider, Rx, medication, delivery	FDA-approved brand-name only, as of March 2026
Ro	~$199+/month	Provider, Rx, medication, support	Compounded and brand-name options
Noom GLP-1	Varies by plan; microdose options added mid-2026	Provider, Rx, medication, behavioral coaching	Compounded semaglutide/tirzepatide
Walgreens Weight Management	$49 visit + ~$149+/month medication	Provider visit, FDA-approved Rx, medication	FDA-approved brand-name only

Note on Hims & Hers: as part of its March 2026 settlement with Novo Nordisk, Hims & Hers agreed to stop marketing compounded semaglutide and now sells Novo Nordisk's FDA-approved Ozempic and Wegovy at self-pay prices instead. If you're comparing an older review that lists Hims as a cheap compounded option, that offer no longer applies.

Why This Category Is Growing

The appeal is simplicity: no navigating insurance denials, no prior authorizations, no pharmacy callbacks. The 2026 shift is that several of the biggest names in this category have moved — voluntarily or under manufacturer/regulatory pressure — from compounded product toward FDA-approved brand-name self-pay medication. If a specific platform's compounded offering matters to your decision, verify its current legal status directly; this segment has changed materially within the past several months and is likely to keep changing through the FDA's public comment period (ending June 29, 2026) on its proposed compounding ban.

Complete Cost Comparison: All Options Side by Side

Here is every legitimate pathway ranked roughly by monthly out-of-pocket cost, updated for mid-2026:

Pathway	Approx. Monthly Cost	Best For	Key Limitation
Manufacturer PAP	$0	Low-income uninsured	Income limits apply (~$63,840/yr single, 2026)
Medicare GLP-1 Bridge	$50 copay	Medicare Part D members with obesity	Covers Wegovy/Zepbound/Foundayo only; runs through Dec 2027
Compounded semaglutide (cheapest)	$169–$249	Budget-conscious, comfortable with regulatory uncertainty	Not FDA-approved; legal lane narrowing in 2026
Wegovy pill (intro pricing)	$149	Want FDA-approved oral option	Price rises after Aug 31, 2026 (to $199 for 4mg)
TrumpRx / NovoCare / LillyDirect intro	$149–$299	Want brand-name, FDA-approved	Some prices are new-patient-only or dose-limited
Compounded tirzepatide	$169–$400	Want dual GIP/GLP-1 mechanism, budget option	Fewer providers; same regulatory uncertainty as semaglutide
LillyDirect Zepbound vial (5mg–15mg)	$399–$449	Need brand-name tirzepatide, refill on schedule	Price jumps to $599–$1,049 if refill window missed
GoodRx (ongoing, after intro)	$349–$399	Need brand-name ongoing	More expensive than TrumpRx/LillyDirect long-term
International pharmacy	$200–$450	Want brand-name, accept import gray area	Import/counterfeit risk
Full retail, no discount	$968–$1,637	Nobody should be paying this in 2026	—

Which Option Should You Choose? A Decision Framework

Choosing the right cost-saving pathway depends on your specific situation. Here is a practical decision tree:

If you are uninsured and earn under about $63,840/year (single) or $86,000/year (household of 2):

Start with manufacturer Patient Assistance Programs (PAPs). Apply to NovoCare or Lilly Cares first — this step costs you nothing but the time to apply, and the potential savings are the largest available.

If you are uninsured and earn above those thresholds:

Compare LillyDirect's Zepbound vial pricing ($299–$449/month) or TrumpRx/NovoCare Wegovy pricing ($149–$299/month) against compounded options. The brand-name self-pay prices have dropped enough in 2026 that compounding is no longer automatically the cheapest or lowest-risk path — run the actual numbers for your dose before assuming compounded is cheaper.

If you want brand-name medication:

Use TrumpRx ($149–$299/month) or NovoCare/LillyDirect introductory pricing directly. Check whether your state Medicaid program covers GLP-1s, as several states added coverage in 2025–2026.

If you want an oral option:

The Wegovy pill at $149/month (through NovoCare's self-pay offer, rising to $199 for the 4mg dose after August 31, 2026) is a strong FDA-approved oral option. Lilly's newly approved Foundayo (orforglipron) is also available via LillyDirect and, through TrumpRx, priced comparably for a starting dose.

If you are on Medicare:

The Medicare GLP-1 Bridge program, active since July 1, 2026, covers Wegovy, Zepbound, and Foundayo at a $50 copay per 30-day supply for eligible members with obesity, through December 31, 2027. Ozempic and Mounjaro (diabetes-indicated) are covered separately under standard Part D rules, not the Bridge program. Manufacturer self-pay savings cards typically exclude Medicare patients.

If you have diabetes (type 2):

You may have additional insurance pathways since GLP-1s for diabetes have broader coverage than GLP-1s for weight loss. Check your plan's formulary — many commercial plans cover Ozempic or Mounjaro for diabetes with reasonable copays even if they don't cover them for weight loss.

If you specifically need tirzepatide (Mounjaro/Zepbound):

Our Zepbound complete guide covers the drug's full clinical profile alongside cost-saving paths. LillyDirect's vial program ($299–$449/month within the refill window) is the most straightforward brand-name path. Compounded tirzepatide remains available from select telehealth platforms at roughly $200–$400/month, but carries the same 2026 regulatory uncertainty as compounded semaglutide.

If you want the strongest weight loss results:

Tirzepatide (Mounjaro/Zepbound or compounded tirzepatide) has shown greater average weight loss in clinical trials than semaglutide. If maximizing weight loss is your priority and budget allows, brand-name tirzepatide via LillyDirect or TrumpRx now costs little more than many compounded options — worth comparing directly rather than assuming compounded is cheaper.

For help choosing the right GLP-1 medication for your specific goals, see our guide to choosing between GLP-1s for weight loss vs diabetes.

How to Verify a Compounding Pharmacy Is Legitimate

Because compounded semaglutide and tirzepatide remain the cheapest options for some patients — and also carry the most quality and regulatory variability in 2026 — verification matters more than ever. Here is a step-by-step process:

Check 503A/503B registration and status: Search the FDA's list of registered outsourcing facilities at FDA.gov. Confirm the pharmacy is currently permitted to compound semaglutide/tirzepatide — this is changing as the FDA's proposed bulk-compounding ban moves through its comment period (ending June 29, 2026).
Look for PCAB accreditation: Visit the Accreditation Commission for Health Care (ACHC) website to verify PCAB status. PCAB-accredited pharmacies undergo inspections beyond basic state requirements.
Request a Certificate of Analysis (COA): Any legitimate pharmacy should provide a COA showing potency, sterility, and endotoxin testing for each batch. If a pharmacy refuses or says it doesn't have one, that's a dealbreaker — walk away.
Verify USP compliance: Ask whether the pharmacy follows USP 797 (sterile compounding) and USP 795 (non-sterile compounding) standards.
Check state licensing: Verify the pharmacy is licensed in your state through your state Board of Pharmacy website.
Confirm who is actually compounding the medication: Several telehealth brands market compounded GLP-1s but route the actual compounding to a separate pharmacy — ask directly, and check for recent FDA warning letters against either party.
Ask about dose consistency: A reputable pharmacy should be able to confirm that the price stays the same across dose levels. If a provider charges substantially more as your dose increases, ask why.

The Price Trajectory: Where GLP-1 Costs Are Heading

Several factors will shape GLP-1 pricing through the rest of 2026 and beyond:

Generic semaglutide is not imminent in the US. Semaglutide's composition-of-matter patents expired in 2026 in some markets (India, China, Canada, Brazil, Turkey), triggering early generic competition abroad. In the US, however, the earliest realistic date for a true generic injectable semaglutide is around 2033, absent a successful patent challenge — not 2026 or 2027. Don't wait for a US generic to make near-term budgeting decisions. For the latest, see our generic semaglutide coverage.
Oral formulations are already here. Beyond the Wegovy pill, Lilly's oral orforglipron won FDA approval as Foundayo on April 1, 2026 — the first non-peptide oral GLP-1 for obesity, taken once daily with no food or water timing restrictions. It's available via LillyDirect and, through TrumpRx, priced competitively with the Wegovy pill. Our next-gen GLP-1 pipeline article tracks what else is coming.
TrumpRx pricing may continue to move. The administration has signaled an intent to push prices lower over time through continued manufacturer negotiations, though specific multi-year price targets haven't been confirmed by the manufacturers themselves — treat projections beyond the current listed prices as directional, not guaranteed.
Employer coverage is under cost pressure, not straightforwardly expanding. Mercer's 2026 survey found roughly 44% of large employers (500+ employees) now cover GLP-1s for weight loss — but the same survey found 6% of employers dropped coverage in 2026 and another 5% are considering dropping it for 2027, as employers grapple with the cost of covering these drugs at scale. The trend is mixed, not a straight line toward universal coverage.
Telehealth competition and enforcement are both intensifying. More platforms have entered the compounded and brand-name self-pay markets, but the FDA's 2026 enforcement wave (50+ warning letters, a proposed bulk-compounding ban) is simultaneously shrinking the compounded segment. Expect continued consolidation toward FDA-approved self-pay pricing.
Retail pharmacy entry continues. Walgreens and other major retailers now offer integrated weight-management programs with GLP-1 access, adding competitive pressure alongside the manufacturer-direct channels.

Frequently Asked Questions

What is the absolute cheapest GLP-1 medication without insurance in 2026?

If you qualify for a manufacturer Patient Assistance Program based on income (roughly under $63,840/year for a single person, 400% of the 2026 federal poverty level), you can get brand-name GLP-1s free or at steep discount — that's the actual cheapest path. Among paid options, compounded semaglutide from telehealth platforms starts around $169–$249/month, though the legal landscape for compounding is narrowing in 2026. Among FDA-approved brand-name options, the Wegovy pill and TrumpRx's Wegovy pill listing are both $149/month.

Is compounded semaglutide the same as Ozempic?

Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy, but it is not an identical, FDA-reviewed finished product. Compounded versions are mixed by pharmacies rather than manufactured by Novo Nordisk, so they lack FDA approval as a finished drug and quality can vary between pharmacies — which is why choosing a PCAB-accredited or properly registered pharmacy matters. In 2026, the FDA has also proposed permanently banning bulk compounding of semaglutide, which would further narrow where compounded product can legally come from.

Will Medicare cover GLP-1 weight loss drugs in 2026?

Yes, as of July 1, 2026, the Medicare GLP-1 Bridge program covers Wegovy, Zepbound, and the newly approved Foundayo for eligible Part D members with obesity, at a $50 copay per 30-day supply that doesn't count toward the deductible or out-of-pocket max. The program runs through December 31, 2027. Ozempic and Mounjaro, which are approved for diabetes rather than weight loss, are covered separately under standard Part D diabetes-drug rules.

How does TrumpRx work for GLP-1 savings?

TrumpRx (trumprx.gov) is a government portal, launched February 5, 2026, that routes patients to Novo Nordisk's and Eli Lilly's own self-pay pricing under the November 2025 federal pricing agreements. It lists Ozempic and the Wegovy pen at $199/month, the Wegovy pill at $149/month, and Zepbound at $299/month. No income verification is required. Confirm current listings directly on trumprx.gov, since manufacturer pricing has changed more than once in 2026.

Are international pharmacies a safe option for buying GLP-1 drugs?

Ordering from verified Canadian pharmacies through organizations like CIPA or PharmacyChecker can provide genuine brand-name GLP-1 medications at meaningful savings versus US retail. However, the FDA technically prohibits personal importation; enforcement has historically been limited for small personal-use quantities, but this is enforcement discretion, not a legal guarantee, and risks include counterfeit products. With LillyDirect and TrumpRx now offering brand-name self-pay prices in the $149–$449 range, the cost advantage of importing from Canada has narrowed considerably compared to a year or two ago.

How much does Zepbound cost without insurance in 2026?

Through LillyDirect's Self Pay Journey Program, Zepbound vials run $299/month (2.5mg), $399/month (5mg), and $449/month (7.5mg–15mg) as long as you refill within 45 days of your last delivery; miss that window and the higher doses jump to $599–$1,049. Without any discount, the Zepbound auto-injector pen lists around $1,059–$1,087/month. Compounded tirzepatide (same active ingredient) is available from select telehealth platforms for roughly $200–$400/month, with the regulatory caveats described above.

Do GLP-1 prices stay the same as my dose increases?

It depends on the pathway. Most compounded semaglutide/tirzepatide programs charge a flat monthly rate regardless of dose — one of their advertised advantages. Brand-name medications through LillyDirect and NovoCare do scale with dose: LillyDirect's Zepbound vials step from $299 to $449 as dose increases, and NovoCare's Wegovy pen steps from $199 (intro) to $349–$399 depending on dose. Always confirm dose-based pricing before committing to a program.

Can I switch between compounded and brand-name GLP-1 medications?

Yes. Many patients start with brand-name GLP-1s using introductory pricing (TrumpRx, NovoCare, or LillyDirect) and stay there now that self-pay brand-name prices have dropped; others start with compounded product to see if they tolerate the medication, then switch to brand-name for the consistency of an FDA-approved product. Your prescribing provider can help manage the transition — doses aren't always directly interchangeable between compounded and brand-name formulations, so a brief adjustment period may be needed.

What happened to compounded semaglutide after the FDA shortage ended?

This is one of the most consequential regulatory shifts of 2026 for patients relying on compounded GLP-1s. The FDA declared the semaglutide shortage resolved in February 2025, which removed the legal basis for mass compounding. Since then, the agency has issued 50+ warning letters to compounders and telehealth firms in 2026 and, in spring 2026, proposed permanently barring semaglutide, tirzepatide, and liraglutide from bulk 503B compounding (public comment period through June 29, 2026). Hims & Hers exited the compounded-semaglutide market entirely in March 2026 as part of a settlement with Novo Nordisk. Some platforms continue offering compounded product under narrower 503A patient-specific rules; patients using compounded GLP-1s should have a backup plan — either transitioning to brand-name self-pay pricing (now considerably cheaper than it was in 2024–2025) or confirming their current provider's compliance status directly.

The Bottom Line

Nobody should pay full retail price for GLP-1 medications in 2026. Between the Medicare GLP-1 Bridge ($50/month copay for qualifying members), manufacturer PAPs ($0 for qualifying patients), TrumpRx and NovoCare/LillyDirect self-pay pricing ($149–$299/month for a starting dose), LillyDirect's Zepbound vial program ($299–$449/month), and compounded options (roughly $169–$400/month, with real regulatory caveats in 2026), the gap between GLP-1 list prices and what an informed patient actually pays has never been wider.

The smartest strategy: apply for manufacturer assistance first, use TrumpRx or manufacturer introductory pricing for brand-name product, and treat compounded semaglutide/tirzepatide as a value option to evaluate carefully given the FDA's active 2026 enforcement push — not as an automatic default the way it may have been in 2023–2024. If you prefer an oral option, the Wegovy pill and the newly approved Foundayo are both legitimate, FDA-approved contenders at $149/month starting-dose pricing.

With brand-name self-pay prices already down sharply in 2026 and a true US generic semaglutide still roughly a decade away, the practical path to an affordable GLP-1 today runs through the manufacturer programs and federal pricing deals covered above — not through waiting for a cheaper option to arrive on its own.

For a comprehensive look at all GLP-1 medications and how they compare, see our best GLP-1 medications for weight loss guide. And if you are new to GLP-1 therapy entirely, our beginner's guide covers everything you need to know before starting.